| Autor: |
Emel Ebru Pala, Ümit Bayol, Alp Özgüzer, Ülkü Küçük, Çağlar Yıldız Akdeniz, Özlem Sezer |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
European Journal of Breast Health, Vol 11, Iss 1, Pp 10-16 (2015) |
| Druh dokumentu: |
article |
| ISSN: |
2587-0831 |
| DOI: |
10.5152/tjbh.2014.2103 |
| Popis: |
Objective:Human epidermal growth factor receptor 2 (HER2) oncoprotein is overexpressed in 15-25% of breast carcinomas and associated with poor outcome. Assessment of HER2 status accurately is important to select patients who will benefit from targeted therapy.Materials and Methods:In this study immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to determine the HER2 status in 308 breast carcinoma cases of which 129 were consultation. The major problems in determining HER2 status and the reasons of discordant results between methods were discussed.Results:HER2 expression was (-) in 124, (+) in 29, (++) in 92, (+++) in 63 cases. 25 of 76 cases consulted as (++) were evaluated as (++) and 15 of 35 cases consulted as (+++) were evaluated as (+++). HER2 amplification was found in 88 (28.6%) of 308 cases by FISH. 3 of 124 (-), 1 of 29 (+), 22 of 92 (++), 62 of 63 (+++) cases were amplified by FISH. The relation between HER2 expression and amplification was statistically significant (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
